Clinical trial NCT04418765: A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
Official title: Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Migraine
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2020-06-05
Enrollment: 892
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.

Detailed description: The total study duration from the screening visit to the completion visit is approximately 76 weeks and includes a screening period (28-30 days), a placebo-controlled treatment period (24 weeks) and a treatment extension period (48 weeks).

The participant will start treatment at the baseline visit and follow a 12-week dosing schedule with either eptinezumab (100 or 300 milligrams \[mg\]) or placebo by intraveneous (IV) infusion. Participants who were assigned to placebo in the placebo-controlled treatment period, will be randomly allocated to one of two treatment groups: eptinezumab 300 mg or eptinezumab 100 mg.

Eligibility criteria: Inclusion Criteria:

* The participant has a diagnosis of migraine, with a history of chronic or episodic migraines of at least 12 months prior to the Screening Visit
* The participant has a migraine onset of ≤50 years of age.
* The participant has ≥4 migraine days per month for each month within the past 3 months prior to the Screening Visit.
* The participant has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit.
* The participant fulfils the following criteria for chronic migraine (CM) or episodic migraine (EM) in prospectively collected information in the eDiary during the screening period:
* For participants with CM: Migraine occurring on ≥8 days and headache occurring on \>14 days
* For participants with EM: Migraine occurring on ≥4 days and headache occurring on ≤14 days
* The participant has documented evidence of treatment failure (must be supported by medical record or by physician's confirmation specific to each treatment) in the past 10 years of 2-4 different migraine preventive medications.
* The participant has a history of either previous or active use of triptans for migraine.

Exclusion Criteria:

* The participant has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway.
* The participant has a treatment failure on valproate/divalproex or botulinum toxin A/B and the treatment is not the latest preventive medication prior to study inclusion. The medication is regarded as the latest if the medication start date is after the start date of the other preventive medications and the medication stop date is after the stop date of the other preventive medications.
* The participant has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
* The participant has a diagnosis of acute or active temporomandibular disorder.
* The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
* The participant has a psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania in the last 5 years prior to the Screening Visit are excluded.
* The participant has a history of clinically significant cardiovascular disease or vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).

Other in- and exclusion criteria may apply

Primary outcomes:
measure: Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12
timeFrame: Baseline, Weeks 1 - 12
Secondary outcomes:
measure: Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
timeFrame: Baseline to Weeks 1 - 12
measure: Change From Baseline in the Number of MMDs Averaged Over Weeks 13 to 24
timeFrame: Baseline, Weeks 13 - 24
measure: Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
timeFrame: Baseline to Weeks 1 - 12
measure: Change From Baseline in the Headache Impact Test (HIT-6) Score at Week 12
timeFrame: Baseline, Week 12
measure: Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24
timeFrame: Baseline to Weeks 13 - 24
measure: Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24
timeFrame: Baseline to Weeks 13 - 24
measure: Percentage of Participants With 100% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
timeFrame: Baseline to Weeks 1 - 12
measure: Percentage of Participants With ≥50% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
timeFrame: Baseline to Weeks 1 - 12
measure: Percentage of Participants With ≥75% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
timeFrame: Baseline to Weeks 1 - 12
measure: Percentage of Participants With 100% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
timeFrame: Baseline to Weeks 1 - 12
measure: Change From Baseline in the Number of MHDs Averaged Over Weeks 1 to 12
timeFrame: Baseline, Weeks 1 - 12
measure: Change From Baseline in the Percentage of Migraine Attacks With Severe Pain Intensity Averaged Over Weeks 1 to 12
timeFrame: Baseline, Weeks 1 - 12
measure: Change From Baseline in the Percentage of Headache Episodes With Severe Pain Intensity Averaged Over Weeks 1 to 12
timeFrame: Baseline, Weeks 1 - 12
measure: Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 1 to 12
timeFrame: Baseline, Weeks 1 - 12
measure: Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 13 to 24
timeFrame: Baseline, Weeks 13- 24
measure: Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 1 to 12
timeFrame: Baseline, Weeks 1 - 12
measure: Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 13 to 24
timeFrame: Baseline, Weeks 13 - 24
measure: Patient Global Impression of Change (PGIC) Score at Week 12
timeFrame: Week 12
measure: PGIC Score at Week 24
timeFrame: Week 24
measure: Change From Baseline in the Number of MMDs in Participants With Medication Overuse Headache (MOH) Averaged Over Weeks 1 to 12
timeFrame: Baseline, Weeks 1 - 12
measure: Percentage of Participants With Migraine on the Day After First Dosing
timeFrame: Day 1
measure: Most Bothersome Symptom (MBS) Score at Week 12
timeFrame: Week 12
measure: Change From Baseline in the HIT-6 Score at Week 24
timeFrame: Baseline, Week 24
measure: Change From Baseline in the Migraine-Specific Quality of Life (MSQ) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in the MSQ Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24
timeFrame: Baseline, Week 24
measure: Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) VAS Score at Week 24
timeFrame: Baseline, Week 24
measure: Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in the WPAI Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24
timeFrame: Baseline, Week 24
measure: Percentage of Participants With ≥5-Point Reduction From Baseline to Week 12 in HIT-6 Score
timeFrame: Baseline to Week 12
measure: Percentage of Participants With ≥5-Point Reduction From Baseline to Week 24 in HIT-6 Score
timeFrame: Baseline to Week 24
measure: Health Care Resource Utilization (HCRU): Visits to a Family Doctor/General Practitioner
timeFrame: Week 12
measure: HCRU: Visits to a Specialist
timeFrame: Week 12
measure: HCRU: Number of Emergency Department Visits Due to Your Migraine
timeFrame: Week 12
measure: HCRU: Number of Hospital Admissions Due to Migraine
timeFrame: Week 12
measure: HCRU: Total Number of Overnight Hospital Stays Due to Migraine
timeFrame: Week 12
measure: Change From Baseline in the Number of MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
timeFrame: Baseline, Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
measure: Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
timeFrame: Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
measure: Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
timeFrame: Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
measure: Change From Baseline in HIT-6 Score at Weeks 36, 48, 60, and 72
timeFrame: Baseline, Weeks 36, 48, 60, and 72
Other outcomes:
Locations:
city: Walnut Creek
country: United States
facility: Diablo Clinical Research
state: California
city: Gainesville
country: United States
facility: Sarkis Clinical Trials - Gainesville
state: Florida
city: Maitland
country: United States
facility: Accel Research Sites - Maitland
state: Florida
city: Ann Arbor
country: United States
facility: Michigan Headache and Neurological Institute
state: Michigan
city: Minneapolis
country: United States
facility: Clinical Research Institute Inc. - Minneapolis
state: Minnesota
city: Albuquerque
country: United States
facility: Albuqerque Clinical Trials
state: New Mexico
city: Amherst
country: United States
facility: Dent Neurologic Institute - Amherst
state: New York
city: Brooklyn
country: United States
facility: Integrative Clinical Trials
state: New York
city: Cincinnati
country: United States
facility: CTI Clinical Research Center
state: Ohio
city: Dayton
country: United States
facility: Hometown Urgent Care & Occupational Health/Hometown Research - Huber Heights
state: Ohio
city: Oklahoma City
country: United States
facility: Lynn Health Science Institute - Oklahoma City
state: Oklahoma
city: Memphis
country: United States
facility: Clinical Neuroscience Solutions - Memphis
state: Tennessee
city: Bellevue
country: United States
facility: Northwest Clinical Research Center (NWCRC)
state: Washington
city: Spokane
country: United States
facility: Northwest Neurological
state: Washington
city: Brussels
country: Belgium
facility: Universitair Ziekenhuis Brussel
state: Bruxelles-Capitale
city: Hasselt
country: Belgium
facility: Jessa Ziekenhuis - Campus Virga Jesse
state: Limburg
city: Gent
country: Belgium
facility: Universitair Ziekenhuis Gent
state: Oost-Vlaanderen
city: Brugge
country: Belgium
facility: Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan
state: West-Vlaanderen
city: Sofia
country: Bulgaria
facility: Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
state: Sofia City
city: Sofia
country: Bulgaria
facility: First Multiprofile Hospital for Active Treatment - Sofia
state: Sofia City
city: Pleven
country: Bulgaria
facility: Multiprofile Hospital for Active Treatment Heart and Brain EAD
city: Ruse
country: Bulgaria
facility: Medical Center - Teodora EOOD
city: Sofia
country: Bulgaria
facility: Acibadem City Clinic Tokuda Hospital
city: Veliko Tarnovo
country: Bulgaria
facility: Medical Center Medica Plus
city: Hradec Kralove
country: Czechia
facility: MUDr. Helena Hojdíkova s.r.o. Neurologicka Ambulance
state: Hradec Kralové
city: Rychnov nad Kneznou
country: Czechia
facility: Vestra Clinics
state: Hradec Kralové
city: Brno
country: Czechia
facility: CCR Brno
state: Jihormoravsky Kraj
city: Ostrava-Poruba-Poruba
country: Czechia
facility: Fakultni nemocnice Ostrava
state: Moravian-Silesian
city: Praha 4
country: Czechia
facility: Fakultní Thomayerova nemocnice
state: Prague
city: Praha 6
country: Czechia
facility: Neurologicka Ambulance - Forbeli
state: Prague
city: Praha 6
country: Czechia
facility: Neuropsychiatrie S.R.O.
state: Prague
city: Praha 8
country: Czechia
facility: Institut Neuropsychiatrické Péce
state: Prague
city: Praha 3
country: Czechia
facility: CCR Prague
state: Praha
city: Ostrava
country: Czechia
facility: CCR Ostrava
state: Severomoravsky Kraj
city: Brno
country: Czechia
facility: Fakultní Nemocnice u sv. Anny v Brne
state: South Moravian
city: Jihlava
country: Czechia
facility: Nemocnice Jihlava
city: Litomyshl
country: Czechia
facility: Neurosanatio s.r.o
city: Slezska Ostrava
country: Czechia
facility: Neurologie, MP-neuro s.r.o., poliklinika Modry pavilon
city: Zlín
country: Czechia
facility: NeuroMed Zlín s.r.o.
city: Glostrup
country: Denmark
facility: Rigshospitalet Glostrup
state: Hovedstaden
city: Odense
country: Denmark
facility: Odense Universitetshospital
state: Syddanmark
city: Esbjerg
country: Denmark
facility: Sydvestjysk Sygehus - Esbjerg
city: Tampere
country: Finland
facility: Tampereen Yliopistollinen Sairaala
state: Länsi-Suomen Lääni
city: Helsinki
country: Finland
facility: Terveystalo Ruoholahti
state: Southern Finland
city: Turku
country: Finland
facility: Terveystalo Turku Pulssi
state: Western Finland
city: Kuopio
country: Finland
facility: Itä-Suomen Yliopisto - Kuopion Kampus
city: Tampere
country: Finland
facility: Terveystalo Tampere
city: Nice Cedex 1
country: France
facility: Hôpital Cimiez
state: Côte-d'Or
city: Rouen
country: France
facility: Hôpital Charles-Nicolle
state: Haute-Normandie
city: Lille Cedex
country: France
facility: Hôpital Roger Salengro
state: Nord
city: Angers
country: France
facility: Centre Hosptitalier Universitaire d'Angers
state: Pays De La Loire
city: Marseille cedex 5
country: France
facility: Assistance Publique Hôpitaux de Marseille
state: Provence Alpes Cote D'Azure
city: Bron
country: France
facility: Hôpital Pierre Wertheimer
state: Rhone-Alps
city: T'bilisi
country: Georgia
facility: Helsicore - Israeli-Georgian Medical Research Clinic
state: Tbilisi
city: T'bilisi
country: Georgia
facility: LLC Todua Clinic
state: Tbilisi
city: Tbilisi
country: Georgia
facility: Pineo Medical Ecosystem
city: Tbilisi
country: Georgia
facility: Archangel Saint Michael Multiprofile Clinical Hospital
city: Tbilisi
country: Georgia
facility: Aversi Clinic - Central Branch
city: Tbilisi
country: Georgia
facility: Mediclub Georgia Medical
city: Tbilisi
country: Georgia
facility: Jerarsi Clinic
city: Tbilisi
country: Georgia
facility: Malkhaz Katsiashvili Multiprofile Emergency Center
city: Tbilisi
country: Georgia
facility: Simon Khechinashvili University Hospital
city: Tbilisi
country: Georgia
facility: Consilium Medulla Multiprofile Clinic
city: Ostfildern
country: Germany
facility: MVZ Dr. Roth & Kollegen GbR
state: Baden-Wuerttemberg
city: Mannheim
country: Germany
facility: Neuroplus
state: Baden-Württemberg
city: Stuttgart
country: Germany
facility: NeuroConcept AG
state: Baden-Württemberg
city: Nürnberg
country: Germany
facility: Praxis Dr. Steinwachs
state: Bayern
city: Hamburg
country: Germany
facility: CTC North
state: Hamburg (Hansestadt)
city: Königstein Im Taunus
country: Germany
facility: Migräne- und Kopfschmerzklinik Königstein
state: Hessen
city: Frankfurt am Main
country: Germany
facility: Synexus - Prüfzentrum Frankfurt/Main
state: Hesse
city: Westerstede
country: Germany
facility: Studienzentrum Nord West
state: Niedersachsen
city: Bielefeld
country: Germany
facility: Neurozentrum Bielefeld
state: Nordrhein-Westfalen
city: Bochum
country: Germany
facility: Neurologische Praxis Dr. Stude
state: Nordrhein-Westfalen
city: Essen
country: Germany
facility: Praxis Astrid Gendolla
state: Nordrhein-Westfalen
city: Essen
country: Germany
facility: Universitätsklinikum Essen
state: Nordrhein-Westfalen
city: Leipzig
country: Germany
facility: Synexus - Leipzig
state: Sachsen
city: Berlin
country: Germany
facility: Synexus Clinical Research - Berlin
city: Unterhaching
country: Germany
facility: Neuropraxis München Süd
city: Esztergom
country: Hungary
facility: Valeomed Diagnosztikai Kozpont
state: Komarom-Esztergom County
city: Kistarcsa
country: Hungary
facility: Pest Megyei Flor Ferenc Korhaz
state: Pest
city: Budapest
country: Hungary
facility: UNO Medical Trials Kft.
city: Rome
country: Italy
facility: Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana
state: Roma
city: Roma
country: Italy
facility: Universita Campus Bio-Medico di Roma
state: Rome
city: Roma
country: Italy
facility: Azienda Ospedaliera - Universitaria Sant' Andrea
state: Rome
city: Bologna
country: Italy
facility: IRCCS Istituto Delle Scienze Neurologiche di Bologna
city: Florence
country: Italy
facility: Azienda Ospedaliero - Universitaria Careggi
city: Pavia
country: Italy
facility: Fondazione Mondino - Istituto Neurologico Nazionale a Carattere Scientifico IRCCS
city: Wroclaw
country: Poland
facility: Centrum Medyczne Oporow
state: Dolnoslaskie
city: Bydgoszcz
country: Poland
facility: Centrum Medyczne Pratia - Bydgoszcz
state: Kujawsko-pomorskie
city: Lublin
country: Poland
facility: Prywatny Gabinet Lekarski Urszula Chyrchel-Paszkiewicz
state: Lubelskie
city: Lublin
country: Poland
facility: Indywidualna Praktyka Lekarska dr hab. n. med. Anna Szczepanska-Szerej
state: Lubelskie
city: Krakow
country: Poland
facility: Pratia MCM Krakow
state: Malopolskie
city: Krakow
country: Poland
facility: Specjalistyczne Gabinety Sp. z o.o.
state: Malopolskie
city: Oswiecim
country: Poland
facility: Instytut Zdrowia dr Boczarska-Jedynak
state: Malopolskie
city: Warszawa
country: Poland
facility: Concept Medica Trials Prywatny Gabinet Lekarski Urszula Chyrchel-Paszkiewicz
state: Mazowieckie
city: Warszawa
country: Poland
facility: SOMED CR - Warsaw
state: Mazowieckie
city: Warszawa
country: Poland
facility: MTZ Clinical Research Powered by Pratia
state: Mazowieckie
city: Gdynia
country: Poland
facility: Synexus - Gdynia
state: Pomorskie
city: Siemianowice Slaskie
country: Poland
facility: Neuro-Care Katowice
state: Silesia
city: Czestochowa
country: Poland
facility: Synexus - Czestochowa
state: Slaskie
city: Katowice
country: Poland
facility: Synexus - Katowice
state: Slaskie
city: Elblag
country: Poland
facility: Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
state: Warminsko-Mazurskie
city: Poznan
country: Poland
facility: Centrum Medyczne Solumed
state: Wielkopolskie
city: Poznan
country: Poland
facility: Synexus - Poznan
state: Wielkopolskie
city: Czestochowa
country: Poland
facility: Centrum Medyczne Pratia - Czestochowa
city: Lodz
country: Poland
facility: SOMED CR - Lodz
city: Moscow
country: Russian Federation
facility: University Headache Clinic
city: Banska Bystrica
country: Slovakia
facility: Neurologicka ambulancia MUDr. Dupejova s.r.o.
city: Bardejov
country: Slovakia
facility: In Medic
city: Dolny Kubin
country: Slovakia
facility: MEDBAJ s.r.o.
city: Dubnica nad Vahom
country: Slovakia
facility: Medicínske Centrum Konzílium - Dubnica nad Vahom
city: Bilbao
country: Spain
facility: Hospital Universitario de Basurto
state: Biscay
city: Majadahonda
country: Spain
facility: Hospital Universitario Puerta de Hierro - Majadahonda
state: Madrid
city: Pozuelo de Alarcon
country: Spain
facility: Hospital Universitario Quironsalud Madrid
state: Madrid
city: Pamplona
country: Spain
facility: Clinica Universidad de Navarra - Pamplona
state: Navarre
city: Vigo
country: Spain
facility: Hospital Alvaro Cunqueiro - Clinico Universitario Vigo
state: Pontevedra
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
city: Valladolid
country: Spain
facility: Hospital Clínico Universitario de Valladolid
city: València
country: Spain
facility: Hospital Clínico Universitario de Valencia
city: Zaragoza
country: Spain
facility: Hospital Clinico Universitario Lozano Blesa
city: Värnamo
country: Sweden
facility: Migränkliniken Europa AB
state: Kronoborgs Län
city: Helsingborg
country: Sweden
facility: Stortorgets neurologmottagning
state: Skåne Län
city: Kristianstad
country: Sweden
facility: Centralsjukhuset Kristianstad
state: Skåne Län
city: Linkoeping
country: Sweden
facility: Universitetssjukhuset i Linköping
state: Östergötlands Län
city: Bellshill
country: United Kingdom
facility: Synexus - Scotland Clinical Research Centre
state: England
city: Chorley
country: United Kingdom
facility: Synexus - The Lancashire Clinic
state: England
city: Edgbaston
country: United Kingdom
facility: Synexus Midlands Clinical Research Centre
state: England
city: Hexham
country: United Kingdom
facility: Synexus - The Hexham Clinic
state: England
city: Liverpool
country: United Kingdom
facility: Synexus - Merseyside Clinical Research Centre
state: England
city: London
country: United Kingdom
facility: Panthera Biopartners - North London
state: England
city: Manchester
country: United Kingdom
facility: Synexus - Manchester Clinical Research Centre
state: England
city: Manchester
country: United Kingdom
facility: Panthera Biopartners - Manchester
state: England
city: Preston
country: United Kingdom
facility: Panthera Biopartners - Preston
state: England
city: Reading
country: United Kingdom
facility: Synexus - Thames Valley Clinical Research Centre
state: England
city: Salford
country: United Kingdom
facility: Northern Care Alliance NHS Foundation Trust
state: England
city: Cardiff
country: United Kingdom
facility: Synexus - Wales
state: Wales
Study officials:
affiliation: LundbeckClinicalTrials@Lundbeck.com
name: Email contact via H. Lundbeck A/S
role: STUDY_DIRECTOR
References:
citation: Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5.